UPSTREAM
29.1.2020 18:57:04 CET | Business Wire | Press release
93 percent of total mobile transactions in 20 countries were blocked as fraudulent in 2019 according to a report on the state of malware and mobile ad fraud released today by mobile technology company, Upstream . The “Invisible Digital Threat ” data is based on deployments of Upstream’s Secure-D full-stack anti-fraud platform that detects and blocks fraudulent mobile transactions mostly originated from ad fraud malware. The platform at the end of 2019 covered 31 mobile operators in 20 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200129005647/en/
In the markets examined, Upstream’s security platform processed 1.71 billion mobile transactions and blocked 1.6 billion of them as fraudulent , a staggering 93 percent of total transactions . It is estimated that left unchecked these transactions would have cost users $2.1bn in unwanted charges . For the industry as a whole, losses from online, mobile and in-app advertising reached $42 billion in 2019 and are expected to reach $100 billion by 20231 .
The number of malicious apps discovered by Secure-D in 2019 rose to 98,000 , up from 63K in 2018. These 98,000 malicious apps had infected 43 million Android devices .
With Android devices now accounting for an estimate 75-85% of all smartphone sales worldwide2 Android is by far the most dominant mobile operating system (OS). At the same time it is the most vulnerable due to its open nature, making it a favorite playground for fraudsters.
While, as mentioned in the Secure-D report, it is always a good rule of thumb for consumers to only download mobile applications from Google’s official storefront, Google Play, thanks to its scale and set up, rogue apps are still getting through its defences. Of the top 100 most active malicious apps that were blocked in 2019, 32 percent are reported still available to download on Google Play . A further 19 percent of the worst-offending apps were previously on Google Play but have since been removed, while the remaining 49 percent are available through third-party app stores.
Fraudsters appear to target some app categories more than others. Ironically, apps designed to make a device function better and make everyday life easier are the ones most likely to be harmful with 22.32 percent of malicious apps for 2019 falling under the Tools / Personalization / Productivity category 3 globally. The next most popular categories cybercriminals target are Games (18.97 percent) and Entertainment/Shopping (15.76 percent).
Indicating scale, in the course of only a few months in 2019, Secure-D reported on the suspicious background activity of five very popular Android apps: 4shared, a popular file-sharing app, Vidmate, a video downloader, Weather Forecast a preinstalled app on Alcatel devices, Snaptube, another video and audio app, and ai.type, an on-screen keyboard app. With a total of nearly 700 million downloads, these were or had been at some point available on Google Play. In these five cases alone, Secure-D detected and blocked 353 million suspicious mobile transactions preventing $430 million in fraudulent charges.
Dimitris Maniatis, CEO of Upstream commented, "Mobile ad fraud is a criminal enterprise on a massive scale. Though it may seem that it is only targeted at advertisers, it greatly affects the whole mobile ecosystem. Most importantly it adversely impacts consumers; eating up their data allowance, bringing unwanted charges, messing with the performance of their device, and even targeting and collecting their personal data. It is more than an invisible threat, it is an epidemic, calling for increased mobile security that urgently needs to rise up in the industry’s priority list. Left unchecked, ad fraud will choke mobile advertising, erode trust in operators and lead to higher tariffs for users" .
The effects of mobile ad fraud are particularly damaging in emerging markets where data costs are significantly higher. As evidenced from detailed data presented from five such markets including Brazil and South Africa fraud rates in most cases exceed the 90% mark. As Upstream’s report highlights consumers in emerging markets are more vulnerable to digital fraud; they are unaware of the dangers as they often go online for the first time via their mobile devices and data depletion caused by malware has a much greater effect on them due to the high cost of data in their countries. In Africa 1 GB of data costs prepaid mobile subscribers the equivalent of 16 hours of work at minimum wage.
Download the full report for an in-depth look at the state and workings of mobile ad fraud including insights on five emerging markets: Brazil, Egypt, Indonesia, South Africa and Ethiopia . By way of comparison, the report also juxtaposes snapshots of the state of malware in the United Kingdom and USA.
-ENDS-
1 Juniper Research
2 Statista and Statcounter
3 As these categories are Google Play Store specific, percentages apply only to apps currently or previously available on Google Play
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
